Cost-effectiveness of exercise referral schemes enhanced by self-management strategies to battle sedentary behaviour in older adults: Protocol for an economic evaluation alongside the SITLESS three-armed pragmatic randomised controlled trial by Deidda, M. et al.
1Deidda M, et al. BMJ Open 2018;8:e022266. doi:10.1136/bmjopen-2018-022266
Open access 
Cost-effectiveness of exercise referral 
schemes enhanced by self-management 
strategies to battle sedentary behaviour 
in older adults: protocol for an economic 
evaluation alongside the SITLESS three-
armed pragmatic randomised controlled 
trial
Manuela Deidda,1 Laura Coll-Planas,2 Maria Giné-Garriga,3 Míriam Guerra-Balic,3 
Marta Roqué i Figuls,2 Mark A Tully,4 Paolo Caserotti,5 Dietrich Rothenbacher,6 
Antoni Salvà Casanovas,2 Frank Kee,4 Nicole E Blackburn,4 Jason J Wilson,4 
Mathias Skjødt,5 Michael Denkinger,7 Katharina Wirth,6,7 Emma McIntosh,1 the 
SITLESS Team
To cite: Deidda M, Coll-
Planas L, Giné-Garriga M, et al.  
Cost-effectiveness of exercise 
referral schemes enhanced by 
self-management strategies 
to battle sedentary behaviour 
in older adults: protocol for 
an economic evaluation 
alongside the SITLESS three-
armed pragmatic randomised 
controlled trial. BMJ Open 
2018;8:e022266. doi:10.1136/
bmjopen-2018-022266
 ►  Prepublication history and 
additional material for this 
paper are available online. To 
view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2018- 
022266). 
Received 14 February 2018
Revised 22 August 2018
Accepted 30 August 2018
For numbered affiliations see 
end of article.
Correspondence to
Dr Manuela Deidda;  
 manuela. deidda@ glasgow. ac. uk
Protocol
© Author(s) (or their 
employer(s)) 2018. Re-use 
permitted under CC BY-NC. No 
commercial re-use. See rights 
and permissions. Published by 
BMJ.
AbstrACt
Introduction Promoting physical activity (PA) and reducing 
sedentary behaviour (SB) may exert beneficial effects 
on the older adult population, improving behavioural, 
functional, health and psychosocial outcomes in addition to 
reducing health, social care and personal costs. This paper 
describes the planned economic evaluation of SITLESS, a 
multicountry three-armed pragmatic randomised controlled 
trial (RCT) which aims to assess the short-term and long-
term effectiveness and cost-effectiveness of a complex 
intervention on SB and PA in community-dwelling older 
adults, based on exercise referral schemes enhanced by a 
group intervention providing self-management strategies to 
encourage lifestyle change.
Methods and analysis A within-trial economic evaluation 
and long-term model from both a National Health Service/
personal social services perspective and a broader societal 
perspective will be undertaken alongside the SITLESS 
multinational RCT. Healthcare costs (hospitalisations, accident 
and emergency visits, appointment with health professionals) 
and social care costs (eg, community care) will be included in 
the economic evaluation. For the cost-utility analysis, quality-
adjusted life-years will be measured using the EQ-5D-5L and 
capability well-being measured using the ICEpop CAPability 
measure for Older people (ICECAP-O) questionnaire. Other 
effectiveness outcomes (health related, behavioural, 
functional) will be incorporated into a cost-effectiveness 
analysis and cost-consequence analysis. The multinational 
nature of this RCT implies a hierarchical structure of the data 
and unobserved heterogeneity between clusters that needs 
to be adequately modelled with appropriate statistical and 
econometric techniques. In addition, a long-term population 
health economic model will be developed and will synthesise 
and extrapolate within-trial data with additional data 
extracted from the literature linking PA and SB outcomes 
with longer term health states. Methods guidance for 
population health economic evaluation will be adopted 
including the use of a long-time horizon, 1.5% discount rate 
for costs and benefits, cost consequence analysis framework 
and a multisector perspective.
Ethics and dissemination The study design was approved 
by the ethics and research committee of each intervention 
site: the Ethics and Research Committee of Ramon Llull 
University (reference number: 1314001P) (Fundació 
strengths and limitations of this study
 ► First economic evaluation of a complex, public 
health intervention to improve health and capability 
outcomes of community-dwelling, insufficiently ac-
tive older adults.
 ► Economic evaluation in a multicountry setting hence 
requires appropriate sensitivity of results to the 
costing methodology and the econometric approach 
to deal with cross-country heterogeneity.
 ► The protocol will provide useful guidance to design 
the economic evaluation of a complex public health 
intervention in multicountry settings.
 ► Economic evaluation will be reported incorporating 
a broad set of preference-based health and capa-
bility outcomes as well as effectiveness outcomes 
using cost-utility, cost-effectiveness and cost-con-
sequence analysis.
 ► While considering sedentary behaviour (SB) along-
side physical activity (PA) represents a strength over 
existing literature, long-term modelling will need 
to rely on assumptions to combine PA and SB and 
validation of this may not be possible until further 
evidence emerges.
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Blanquerna, Spain), the Regional Committees on Health Research Ethics for 
Southern Denmark (reference number: S-20150186) (University of Southern 
Denmark, Denmark), Office for Research Ethics Committees in Northern 
Ireland (ORECNI reference number: 16/NI/0185) (Queen’s University of 
Belfast) and the Ethical Review Board of Ulm University (reference number: 
354/15) (Ulm, Germany). Participation is voluntary and all participants will 
be asked to sign informed consent before the start of the study. This project 
has received funding from the European Union’s Horizon 2020 research 
and innovation programme under grant agreement number 634 270. This 
article reflects only the authors' view and the Commission is not responsible 
for any use that may be made of the information it contains. The findings 
of the study will be disseminated to different target groups (academia, 
policymakers, end users) through different means following the national 
ethical guidelines and the dissemination regulation of the Horizon 2020 
funding agency. Use of the EuroQol was registered with the EuroQol Group in 
2016. Use of the ICECAP-O was registered with the University of Birmingham 
in March 2017.
trial registration number NCT02629666; Pre-results.
IntroduCtIon 
Economics of inactivity and sedentary behaviour
An insufficient level of physical activity and prolonged 
sedentary behaviour (PA and SB, respectively, hence-
forth) is associated with an increased risk of developing 
major diseases (eg, breast and colon cancers, type 2 
diabetes, obesity and depression). Particularly, in the last 
decade, growing evidence indicates that excessive sitting 
time may be harmful to health, independent of meeting 
the recommended PA guidelines.1 
PA and SB represent large costs to the healthcare 
system and society more broadly. In England, the cost of 
physical inactivity among the general population (direct 
costs related to chronic diseases and indirect costs related 
to the loss of productivity associated to mood and anxiety 
disorders) has been estimated to be £8.3 billion per year2 
whereas in Europe that estimate equated €80.4 billion 
in 2012 (6.2% of total healthcare expenditure across the 
EU-28). In this regard, reducing inactivity by 20% among 
the adult population would result in a cost-saving of 
€16.1 billion.3
The burden of an inactive lifestyle is predicted to be 
increasing for older adults, which represent the fastest 
growing segment of the world population,4 accounting for 
30%–40% of total healthcare spending across Europe.5
An increase in the percentage of the total population 
who are older adults will be accompanied by an increase 
in the incidence of diseases associated with old age such as 
cardiovascular disease, cancer, type 2 diabetes, accidental 
falls, obesity, metabolic syndrome, mental disorders and 
musculoskeletal diseases.6 Furthermore, the frailty associ-
ated with old age constitutes an additional risk factor for 
adverse health outcomes (falls, hospitalisation, disability 
and death).7 Maintaining or engaging in a physically 
active lifestyle and reducing SB may result in attenuating 
cognitive and functional decline over time, alleviating the 
symptoms of various chronic conditions associated to old 
age8 and preventing or even reversing frailty.9 10
More broadly, an active lifestyle has the potential to 
increase the elderly well-being, in line with the concept 
of ‘active aging’ and with the aim to ‘extend healthy life 
expectancy and quality of life for all people as they age, 
including those who are frail, disabled and in need of 
care.’11
The substantial economic impact of an inactive lifestyle 
justifies the need for a robust health economic evalua-
tion to report the cost-effectiveness of interventions to 
promote active lifestyles to reduce the likelihood of devel-
oping diseases and disability associated with old age and 
preventing them.
Interventions to reduce sb or a lack of PA: economic 
evaluation evidence
Evidence regarding the cost-effectiveness of public health 
interventions directed towards the increase of PA and 
reduction of SB is typically characterised by a substan-
tial heterogeneity regarding the type of implemented 
intervention and the target population.12 13 Most studies 
analyse the effect of interventions on healthy popula-
tions14 15 or to a population with specific chronic condi-
tions.16–18 Only few focus on older adults,19–21 without 
major health conditions,20 21 with specific chronic condi-
tions19 22 23 or mobility problems.24 25
A review carried out by Owen et al26 pointed out that 
most exercise referral scheme (ERS) interventions 
(among a list of the UK’s National Institute for Health 
and Care Excellence (NICE) public health interventions) 
were under the UK’s £20 000 cost per quality-adjusted life-
year (QALY) threshold, thus representing a cost-effec-
tive use of resources. However, studies usually compare 
ERS with usual care (UC), and evidence is limited or 
plagued by significant uncertainty around estimates of 
cost-effectiveness.27 Garrett et al13 reported the results 
of a systematic review of community-based interventions 
directed towards the improvement of PA, finding that 
most interventions, especially those not requiring direct 
supervision, were cost-effective.23 Pavey et al14 found that 
ERS interventions were cost-effective only in inactive 
but healthy populations.10 de Vries et al24 evaluated the 
cost-effectiveness of a patient-centred physical therapy 
strategy with tailored motivational and coaching sessions 
and physical training directed towards individuals over 
70 years old with mobility problems; they found that the 
intervention was effective in increasing PA and reducing 
frailty and provided good value for money.20
Poor adherence and lack of long-term commitment 
have been identified as the main challenges of ERS inter-
ventions, thus suggesting scope for behavioural inter-
ventions.12 14 However, only few studies evaluate such 
interventions.16 21 Furthermore, there is a lack of evidence 
regarding the long-term effectiveness and cost-effective-
ness of interventions to increase PA and reduce SB.14
the sItLEss intervention
The SITLESS study is a multinational, multicentre, 
three-armed randomised controlled trial (RCT) 
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investigating the short-term and long-term cost-effec-
tiveness of a complex intervention to increase PA and 
reduce SB in older adults from four European coun-
tries. The cost-effectiveness of a joint intervention of 
ERS and self-management strategies (SMS) will be eval-
uated compared with two alternatives: ERS alone and 
usual care (UC) . Full details of the RCT protocol are 
reported elsewhere.28
ERS have become one of the most widely used instru-
ments to promote PA.14 29 In an ERS intervention, individ-
uals—usually insufficiently active or affected by specific 
diseases which might benefit from PA—are assigned 
to a primary care or to an exercise facility (usually in 
the community setting), which design and monitor a 
tailored exercise programme. However, ERS are not 
usually focused on reducing SB20 30–32 and evidence of 
ERS effectiveness typically relates to the short-term as 
well as to specific subgroups of individuals (eg, over-
weight adults, or individuals who are already slightly 
active33) hence they are often not generalisable to the 
older population. Furthermore, evidence regarding the 
effectiveness and cost-effectiveness of ERS compared 
with alternative interventions (eg, standard advice) is 
limited.29 34
Individual commitment towards PA and reduction of 
SB are driven by behavioural, demographic and socioeco-
nomic (possibly country-specific) factors.35 36 Given this, 
the behavioural intervention in the form of SMS could 
modify individual behaviour more effectively than ERS 
or UC.37 Furthermore, SMS might exert an incremental 
benefit—in terms of increased PA and reduction of SB—
with respect to ERS alone, in terms of enhanced motiva-
tion to sustain the behaviour change over the long term, 
thus overcoming problems related to the limited uptake 
and low adherence to the programme which are usually 
associated with ERS.18 19
The SITLESS RCT enhances the PA intervention 
with an SMS intervention based on behavioural change 
techniques, encompassing a range of components: 
behavioural goal setting, self-monitoring of progress and 
social support among peers and the existing network, 
external monitoring, problem solving, environmental 
signposting. The SMS intervention targets PA and SB with 
distinct, through related, techniques.28
This paper describes the protocol for the economic 
evaluation alongside the SITLESS RCT. The aim is to 
determine whether enhancing ERS by SMS is a cost-effec-
tive strategy and provides good value for money. In addi-
tion, this economic evaluation protocol will outline the 
additional challenges posed by the multicountry nature 
of the study, describing the proposed methodologies to 
deal with the identification, measurement and valuation 
of costs and outcomes. The health economics logic model 
(online supplementary appendix 1) illustrates the linkage 
between the resources used and the outcomes of interest 
related to the SITLESS intervention.
MEthods
design
Following good practice for the design of economic evalu-
ations alongside RCTs,38 data collection instruments were 
designed in collaboration with the trial team to collect 
information on the cost of the ERS and SMS intervention, 
resources used by patients (eg, usage of medical, social 
and community services) and preference-based quality of 
life (QOL) and capability outcomes, at baseline and over 
the trial follow-up (12 and 18 months after intervention) 
considering a health and social service perspective and a 
broader social perspective. While the SITLESS complex 
intervention is standardised, the data collection instru-
ments were tailored to each country context (eg, inclu-
sion of country-specific examples of community/social 
services).
The economic evaluation will follow the UK’s most 
recent guidance for the economic evaluation of public 
health interventions NICE,39 as well as Consolidated 
Health Economic Evaluation Reporting Standards 
(CHEERS) guidelines for reporting results.40
study population
The target population is community-dwelling older 
adults who fulfil the following criteria: aged 65 or above; 
able to walk independently for at least 2 min; have no 
major physical limitations (ie, obtaining <4 in the Short 
Physical Performance Battery); and who are insuffi-
ciently active (perform regular PA) for at least 30 min 5 
or more days of the week. All individuals will be recruited 
according to country-specific primary prevention path-
ways. Overall, according to the sample size estimation, 
1338 individuals will be recruited for the trial (446 per 
group).
setting and location
The SITLESS trial is a multicountry, multicentre trial. The 
intervention will be delivered in primary care or commu-
nity settings in four sites: Barcelona (Spain), Odense 
(Denmark), Ulm (Germany) and Belfast (UK).
A multicountry RCT has benefits in terms of higher 
statistical power and generalisability of the economic 
results.41 42 However, the multinational nature of SITLESS 
occasions substantial cross-country heterogeneity in terms 
of: demographic structure (ie, morbidity and mortality 
patterns, ageing structure); differences in healthcare 
systems (eg, payment systems, health provider incen-
tives); differing unit cost sources; differing availability 
of healthcare services and clinical practices43; individual 
attitudes towards PA (personal motivation, health and 
mobility issues, genetic factors); and social and physical 
environments or cultural differences in behaviour and 
preferences of participants (eg, local opportunities to do 
PA, social gathering, etc).
For all the reasons mentioned above, identifying and 
accounting for cross-country heterogeneity is a key issue 
for the economic evaluation of SITLESS.
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Intervention and comparator
The cost-effectiveness of a joint intervention of ERS and 
SMS will be compared (18 months) with two control 
groups: (1) ERS alone; (2) UC (ie, written general booklet 
standardised across sites, including the WHO recommen-
dation regarding PA regular practice for health, and two 
sessions on healthy ageing regarding fall prevention and 
healthy nutrition).
Patient and public involvement
SITLESS, as a Responsible Research and Innovation 
project, has created guidance for the involvement of 
several stakeholders in the project from the onset. They 
comprise older adults of both genders, representatives of 
older adults’ associations, primary healthcare and sports 
professionals, policymakers and other local stakeholders 
of relevance (eg, health insurance, where relevant). 
Accordingly, four local advisory boards were created at the 
beginning of the project, one on each intervention site 
(Barcelona, Odense, Belfast, Ulm), and were periodically 
involved in the study from its onset. The development 
of the research question and outcome measures were 
shared with each advisory board and therefore informed 
according to patients’ priorities and motivations, expe-
rience and preferences. We also did a literature review 
that included how older adults perceive PA and SB, and 
how could we achieve sustained changes of behaviour to 
enhance health.
The involvement of stakeholders as primary, secondary 
and tertiary end users in the design of the study was 
specifically in the intervention design. We explored 
experiences, preferences and priorities of older adults 
regarding behaviour change through focus groups that 
were convened thanks to the older people organisations 
belonging to the local advisory boards. We took into 
account their contributions at each site, and the main 
results were included in the intervention design.
Local advisory boards also discussed and provided their 
contributions to the challenges faced regarding recruit-
ment, retention of participants in the study and the 
dissemination strategies.
Qualitative interviews were conducted with a purposeful 
sample of participants in each intervention site and from 
each arm of the trial to explore their perceptions on the 
intervention.
Once the trial ends, we are planning on disseminating 
the results at each primary care centre and local leisure 
centres to end users, health professionals and relevant 
stakeholders. We would like to share our results to Citizen 
Science events, also involving participants of each site.
study perspective
The economic evaluation will be conducted from a health 
service and personal social services perspective as recom-
mended by UK’s NICE guidelines.39 To this end, health 
and non-health care costs (and cost savings) incurred by 
both the provider and the participant will be considered.
According to NICE guidelines, which suggest empha-
sising overall welfare, rather than health per se, a 
cost-effectiveness analysis (CEA) from a personal social 
services perspective and a cost-consequence analysis 
(CCA) adopting a broader societal perspective may be 
performed as well.
time horizon
The assessment of the primary within-trial economic anal-
ysis will be conducted at baseline, after intervention, and 
at 12 and 18 months’ follow-up. The economic evaluation 
includes a long-term model to extrapolate the cost-ef-
fectiveness results beyond the 18 months within trial 
component.
discount rate
Following UK’s NICE public health economic evaluation 
guidelines,39 a discount rate of 1.5% will be employed 
and sensitivity analysis will explore the impacts of rates of 
3.5% and 6%.
Measures of outcome
The measures of outcome employed in the economic eval-
uation and the timing of their collection are presented in 
table 1. While QALYs are the main outcome measure to 
be used in a cost-utility analysis (CUA) framework, CEA 
and CCA will make use of the broader set of outcomes 
collected within trial.
QALYs will be estimated using the EQ-5D-5L44 and 
capability well-being estimated using the ICEpop Capa-
bility Measure for Older People (ICECAP-O).45 Outcomes 
will be assessed at baseline, month 4 (end of ERS inter-
vention), month 16 (12 months after intervention) and 
month 22 (18 months after intervention) allowing estima-
tion of the area under the curve (AUC). The EQ-5D-5L 
focuses on health attributes while the ICECAP-O instru-
ment will assess capability well-being (according to Sen’s 
capability theory46), thus incorporating both health and 
non-health dimensions.47
QOL: EQ-5D-5L
The EQ-5D-5L questionnaire measures health-related 
quality of life (HRQOL) in terms of five dimensions 
(mobility, self-care, daily activities, pain and discomfort, 
anxiety and depression) in a 1–5 scale. It also includes 
a visual analogue scale on which patients rate their own 
health between 0 (best imaginable health state) and 100 
(worst imaginable health state). Assigning weights to each 
response of the five dimensions, it is possible to generate 
a synthetic index that will summarise the HRQOL at the 
individual level. The EQ-5D has been used by several 
studies examining the cost-effectiveness of ERS as a 
measure of HRQOL.17 19 48
EQ-5D utility scores will be derived using UK tariffs. 
In consideration of the multinational aspect of the anal-
ysis, the quality adjustment weights for each health state 
at different periods should be obtained by using coun-
try-specific EQ-5D tariffs, which reflect country-specific 
differences in health perceptions and preferences and 
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might significantly affect CUA.49–51 However, so far coun-
try-specific sets of tariffs for the EQ-5D-5L have not been 
directly elicited in any of the SITLESS countries with a 
validated procedure (value sets for England only are 
available) and in line with a recent NICE position state-
ment,52 we will make use of the ‘crosswalk’ procedure, 
developed by the EuroQol Group to link the EQ-5D-5L 
and EQ-5D-3L. Crosswalk value sets for the EQ-5D-5L are 
currently available for all the countries participating in 
the SITLESS study.53
The utility value derived from the EQ-5D-5L question-
naire will be used to derive QALYs using standard AUC 
methods, eventually adjusted for group-specific differ-
ences in baseline utility.54
ICEpop Capability Measure for Older People
The ICECAP-O instrument measures capability well-being 
across five capability dimensions (attachment, security, 
role, enjoyment, control). English, Spanish and German 
translations were available for ICECAP-O; however, the 
questionnaire was translated for the first time in Danish 
for the SITLESS trial. Given that country-specific tariffs 
are not available for all the countries in the SITLESS trial, 
the ICECAP-O utility scores were derived using UK tariffs.
resource use
Identification and measurement of resource use
The costs of delivering and administering the SITLESS 
intervention and the control will be identified and 
measured alongside potential cost impacts, thus taking 
into account both costs incurred as well as cost savings 
arising across arms.
In line with the National Health Service and personal 
social services perspective, two sources of costing have 
been taken into account. First, the costs borne by the 
primary care/exercise facility to deliver the SITLESS 
intervention and the control are considered. The SMS 
intervention is tailored to each individual, thus requiring 
the collection of individual-specific costs (eg, duration 
of the contact, staff present, transport costs sustained by 
staff and participants) using the SMS intervention cost 
log. Average costs (eg, equipment used during the SMS 
Table 1 Overview of outcome measures
Measure Means of collection Timing of collection
QALYs
  Quality of life (EQ-5D) Self-reported Baseline (T0), month 4 (end of ERS intervention) 
(T1), month 16 (12 months after intervention) (T2) 
and month 22 (18 months after intervention) (T3)
  Capability in older people (ICECAP-O) Self-reported
Primary outcomes
  SB (measured as sitting time) Face-to-face interview Baseline (T0), month 4 (end of ERS intervention) 
(T1), month 16 (12 months after intervention) (T2) 
and month 22 (18 months after intervention) (T3)
  PA (measured as daily counts/min and daily 
step counts)
Face-to-face interview
Secondary outcomes
  Physical function Face-to-face interview
Baseline (T0), month 4 (end of ERS intervention) 
(T1), month 16 (12 months after intervention) (T2) 
and month 22 (18 months after intervention) (T3)
  Muscle function Face-to-face interview
  Anthropometry Face-to-face interview
  Bioimpedance Face-to-face interview
  Blood pressure Face-to-face interview
  Activities of daily living Self-reported
  Self-rated health and health-related quality of 
life
Self-reported
  Anxiety Self-reported
  Depressive symptoms Self-reported
  Social network Self-reported
  Physical activity self-regulation Face-to-face interview
  Self-efficacy for exercise Face-to-face interview
  Disability Face-to-face interview
  Fear of falling Face-to-face interview
  Loneliness Self-reported
  Executive function Face-to-face interview
  Physical fatigue72 Face-to-face interview
ERS, exercise referral scheme; ICECAP-O, ICEpop Capability Measure for Older People; PA, physical activity; QALY, quality-adjusted life-
years; SB, sedentary behaviour. 
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sessions; refreshments) which are not likely to change 
across individuals will also be identified and measured. 
Unlike the SMS, the delivery of the ERS and UC interven-
tions are entirely standardised. Thus, the associated cost 
can be regarded as uniform and not as an individual-spe-
cific cost. Therefore, the data collection instruments 
(ERS and UC cost logs) aim to capture the average cost 
sustained when delivering these interventions. Specifi-
cally, the ERS cost log identifies and measures: the number 
and type of staff involved in delivering the intervention; 
travel costs sustained by participant and staff; average cost 
of the equipment used, considering the number of equip-
ment used, typical lifespan and cost. A sample of the data 
collection instruments can be provided on request.
Besides the cost of the intervention, a wide range of 
resource use, including use of exercise facilities as well 
as use of health and social services (table 2), will be 
derived through a bottom-up exercise, following similar 
studies14 17 and collected through a questionnaire.
Research costs including the cost of the ActiGraph, 
ActivPal and Axivity accelerometers—used to measure 
PA and SB—will not be included. However, research costs 
related to the recruitment of participants will be identi-
fied and reported (separate from the economic evalua-
tion) to provide likely implementation costs should the 
trial be rolled out in future.
Valuation of resource use
Evaluating costs in multinational trials requires handling 
a non-negligible amount of between-country heteroge-
neity that needs to be tackled appropriately in order to 
allow for comparability.
Unit prices need to be converted into a common 
currency (€) by use of purchasing power parity statistics 
reported by the Organisation for Economic Co-operation 
and Development for a base year to allow proper compar-
ison.41 Furthermore, following a multicountry costing 
approach, unit cost estimates from each country will be 
used to evaluate the resources used in these countries but 
sensitivity analysis using UK unit prices will be performed 
as well. Indeed, while systematic reviews provide mixed 
evidence on the most used costing method,55–57 using 
country-specific unit costs is a common and recom-
mended practice to evaluate resources in multinational 
RCTs.58 59 However, recent ISPOR guidelines cast doubts 
on the superiority of the multicountry approach,58 
arguing that a multicountry costing may not be an effec-
tive strategy to adjust for cross-country heterogeneity.
An overview of resource use and cost measures to be 
employed in the economic evaluation is presented in 
table 2, while online supplementary appendix 2 provides 
a summary of the unit cost sources that will be used to 
value resource use.
sample size
The estimated sample size to assess overall effectiveness of 
the intervention in the clinical trial is 1338 subjects (distrib-
uted in three intervention groups of 446 participants).28 
This sample size will ensure that it is possible to detect a 
clinically relevant increase of 30 daily counts per minute 
(CPM) between the ERS-SMS and the control groups or 
between the ERS-SMS and the ERS groups.
This sample has been estimated in a two-sided test, at a 
power of 80% and an α of 0.05, a common SD of 139 of 
the mean and a 24% dropout rate. A change of 30 CPM 
is considered a measurable moderate effect size in this 
population, assessed with ActiGraph GT3X+, and 139 is 
the SD for CPM found in the literature.60
Within-trial economic analysis
The within-trial economic analysis will establish the 
expected cost-effectiveness of SMS+ERS compared 
with ERS alone and UC through a number of different 
analyses. The main within-trial analysis will be reported 
using a CUA framework, which will calculate the incre-
mental cost per QALY (calculated using EQ-5D). Further 
reporting will include the incremental cost per year of 
full capability (calculated using the ICECAP-O) of the 
SITLESS intervention versus both the control groups. In 
addition, the cost per unit of increased PA or reduction in 
SB will be calculated using a cost-effectiveness framework.
Furthermore, a CCA framework will be also imple-
mented. Given the complex nature of the SITLESS 
intervention, it is likely that all the relevant benefits of 
the intervention will not be captured by a single utility 
measure or a single outcome measure. To this end, the 
CCA framework would facilitate the presentation of a 
wider battery of outcomes collected within the SITLESS 
trial. Table 3 shows the health economics framework 
(CUA, CBA or CCA), and the related outcome measures, 
perspectives and format for presenting results.
statistical analysis
The multicountry nature of the SITLESS intervention 
implies that cost and outcome data fall naturally in a hier-
archical structure, meaning that multiple ‘micro-units’ 
(individuals) are nested within multiple macrounits 
(countries).41 61 Dealing with this hierarchical data struc-
ture will be an important consideration for the economic 
evaluation analysis, and will allow appropriate modelling 
of within and between-country variability as well as the 
clustering effect of the intervention itself.62 63 However, if 
no significant degree of country-level clustering is found 
in the SITLESS data, the estimation will rely on widely 
used non-hierarchical models (eg, a pooled model with 
country fixed effects57).
An exploratory analysis will reveal country patterns in 
cost and effectiveness, as well as highlighting the pres-
ence of outliers that—due to the small number of coun-
tries—may have a stronger impact on economic results.
Addressing uncertainty
Deterministic and stochastic sensitivity analysis will be 
performed to measure uncertainty around parameters 
considered to be influencing the cost-effectiveness of the 
SITLESS intervention.
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Deterministic, one-way sensitivity analysis will examine 
the impact that changes in the discount rate, unit costs 
and utility weights would have on the main economic 
evaluation results. The impact of assumptions regarding 
resource use and outcome valuation in a multicountry 
setting will also be explored, including: (A) multicountry/
one-country (UK unit costs) costing approach; (B) coun-
try-specific utility weights derived through the ‘cross-
walk’ procedure/UK-based EQ-5D. When appropriate, a 
tornado diagram may be used to explore the effect of a 
percentage change in each of the key model parameters 
on the main outcome.
A two-way sensitivity analysis will explore the joint varia-
tion of cost and utility weights around a range identified 
by the one-country and multicountry scenario, and will 
assess how the incremental cost-effectiveness ratio (ICER) 
changes in the ‘extreme’ cases. In addition, sensitivity 
to the econometric specification used to model cross-
country data clustering will be examined and taken into 
account. Further sensitivity analysis might be required 
depending on the distributional assumptions regarding 
cost and outcomes, as well as regarding the presence of 
outliers.
Probabilistic sensitivity analysis (PSA) around the longer 
term estimates of costs, effects and cost-effectiveness of 
the ERS+SMS intervention versus ERS alone and UC will 
be performed using a 1000 iteration Monte Carlo simula-
tion. PSA has the advantage of indicating the probability 
of a technology being cost-effective at various thresholds 
of willingness to pay (WTP). A high probability of being 
cost-effective should lead to a more positive outcome in a 
technology appraisal, whereas the opposite should apply 
for a low probability.64 Using Monte Carlo simulation, 
a bootstrapped distribution of costs and QALY will be 
generated and incremental costs and QALY will be shown 
in a cost-effectiveness plane. Cost-effectiveness accept-
ability curves will graphically represent the probability 
that the intervention is cost-effective compared with the 
controls across a range of cost-effectiveness thresholds. 
Representing the uncertainty of ICER across a range 
of WTP is a key issue in the economic evaluation of the 
SITLESS intervention, given that the WTP is likely to be 
country specific, reflecting a country’s opportunity cost of 
undertaking the intervention.65
Missing data
Following best practice,58 66 67 a multiple imputation 
procedure using chained equations will be used to 
impute missing data separately for each arm of the trial 
and predictive mean matching will allow dealing with 
non-normality of cost and outcome data.68 The procedure 
to deal with missing data will take into account additional, 
SITLESS-specific, reasons for missingness related to the 
fact that motivations and barriers for providing informa-
tion might be age related (eg, physical or cognitive weak-
ness). Furthermore, an analysis of missing data by country 
will be performed in order to identify any country-specific 
pattern in the probability of missingness.
Extrapolation beyond trial: lifetime cost-effectiveness
If evidence of differences between the treatment arms in 
terms of effectiveness, costs or cost-effectiveness is found 
Table 3 Overview of Health Economics frameworks, outcome measures, perspective and format for presenting results 
Health economics 
framework Outcome measure Perspective Format for presenting results
Cost-utility analysis 
(CUA)
EQ-5D Health and personal 
social services
Incremental cost/QALY
Cost-capability well-
being analysis
ICECAP-O Health and personal 
social services
Incremental cost/year in full 
capability
Cost-effectiveness 
analysis (CEA)
Sitting time Health and personal 
social services
Incremental cost/unit of reduction in 
sitting time
Physical activity Health and personal 
social services
Incremental cost /10% of daily step 
count increase 
+ utility measures used in the CUA, as 
above
Cost consequence 
analysis (CCA)
Incremental cost of the 
SMS+ERS intervention versus comparator, 
to be compared with the change in 
secondary outcome (eg, physical function, 
muscle function, anxiety, disability fear of 
falling) 
Societal Cost/change in multiple outcomes, 
for example, change in physical 
function; change in muscle 
function; change in QALY/years in 
full capability; change in daily step 
counts
+ utility measures used in the CUA and 
effectiveness measures used in the CEA, 
as above 
ERS, exercise referral scheme; ICECAP-O, ICEpop Capability Measure for Older People; QALY, quality-adjusted life-years; SMS, self-
management strategies. 
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in the trial, an extrapolation of the within-trial results to 
the long term will be performed following NICE39 guide-
lines. As noted by Pavey et al,14 the long-term effect of an 
increase in PA levels on health gains is not clear, and it 
might be difficult to extrapolate the results beyond the 
observed data. A behavioural Markov model, akin to 
the model developed by Frew et al69 and Roux et al,70 
projecting changes in PA behaviour to health outcomes 
and costs are natural candidates to model the cost-ef-
fectiveness of SITLESS in the long term. However, the 
model will be customised to take specific challenges into 
account, including: (A) inclusion of SB, using available 
evidence to ‘convert’ SB into PA (eg, Ekelund et al71); (B) 
identification of ageing-specific health outcomes; and (C) 
choice of appropriate time horizon, taking into consider-
ation the target population’s life expectancy. Uncertainty 
around the longer term estimates of costs, effects and 
cost-effectiveness of the ERS+SMS intervention versus the 
comparators will be performed using Monte Carlo simu-
lation techniques. An annual discount rate of 1.5% will be 
applied to costs and effects in line with NICE guidelines.39
dIsCussIon
The economic evaluation of the SITLESS intervention 
has been designed to respond to the need to fully evaluate 
a complex intervention on PA and SB in older adults. The 
economic implications of PA and SB are magnified for 
older adults, and may result in a greater use of healthcare 
resources, leading to a burden of cost for national health 
systems and society. Furthermore, behavioural interven-
tions such as the SMS implemented in the SITLESS inter-
vention are suited to addressing matters of long-term 
adherence to the programme, while more standard inter-
ventions have been limited by being effective only in the 
short term.12 14 27
While previous clinical studies have assessed the clinical 
effectiveness of interventions on PA and SB, cost-effec-
tiveness has not often been assessed. On the other hand, 
existing studies refer to interventions implemented in a 
specific context, while, to the best of our knowledge, this 
is the first RCT which focuses on older adults and takes 
the multicountry setting into account.
The multicountry nature of the study poses addi-
tional methodological challenges for the economic anal-
ysis. However, a multinational RCT has the potential to 
increase the generalisability of the results, thus providing 
the policymaker with useful guidelines on the value 
for money provided by complex interventions such as 
SITLESS. Furthermore, an appropriate sensitivity anal-
ysis in the long-term modelling of intervention effects 
will provide insights on their sustainability—taking into 
account intervention costs and adherence to intervention 
programmes similar to SITLESS that are implemented in 
a ‘real world’ context.
In addition to dealing with the multicountry aspect 
of the study, the proposed economic evaluation of 
SITLESS has accounted for several aspects related to the 
complexity of such intervention, including: the existence 
of multiple, interacting components (PA and behavioural 
component); number and difficulty of the behaviours 
required by those delivering the intervention; interdis-
ciplinary team involved; existence of externalities and 
spillovers (eg, to family and informal carers); and inter-
action between users and providers and system-wide 
components. Such a complexity does imply additional 
challenges for the economic evaluation, such as the need 
to consider a plethora of outcomes to take the multidis-
ciplinary aspect of the intervention into account and the 
design of data collection instruments balancing standard-
isation and country tailoring.
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